While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

A quarter-century in any creative field reveals the difference between those who adapt to trends and those who shape them.

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

In the latest trading session, Moderna (MRNA) closed at $26.85, marking a -2.33% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.53%. Elsewhere, the Dow ...

For people whose autumn agenda includes getting vaccinated against respiratory diseases - COVID, flu, and, for some, RSV - ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I would like to receive updates and special offers from Dow ...